Reproductive and Adult Endocrinology Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2011 Sep;96(9):2779-85. doi: 10.1210/jc.2011-0333. Epub 2011 Jul 13.
Accurate diagnosis of head and neck paragangliomas is often complicated by biochemical silence and lack of catecholamine-associated symptoms, making accurate anatomical and functional imaging techniques essential to the diagnostic process.
Ten patients (seven SDHD, three SDHB), with a total of 26 head and neck paragangliomas, were evaluated with anatomical and functional imaging. This study compares five different functional imaging techniques [(18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) positron emission tomography (PET), (18)F-fluorodopamine ((18)F-FDA) PET/computed tomography (CT), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT, (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy, and (111)In-pentetreotide scintigraphy] in the localization of head and neck paragangliomas.
Prospectively (18)F-FDOPA PET localized 26 of 26 lesions in the 10 patients, CT/magnetic resonance imaging localized 21 of 26 lesions, (18)F-FDG PET/CT localized 20 of 26 lesions, (111)In-pentetreotide scintigraphy localized 16 of 25 lesions, (18)F-FDA PET/CT localized 12 of 26 lesions, and (123)I-MIBG scintigraphy localized eight of 26 lesions. Differences in imaging efficacy related to genetic phenotype, even in the present small sample size, included the negativity of (18)F-FDA PET/CT and (123)I-MIBG scintigraphy in patients with SDHB mutations and the accuracy of (18)F-FDG PET/CT in all patients with SDHD mutations, as compared with the accuracy of (18)F-FDG PET/CT in only one patient with an SDHB mutation.
Overall, (18)F-FDOPA PET proved to be the most efficacious functional imaging modality in the localization of SDHx-related head and neck paragangliomas and may be a potential first-line functional imaging agent for the localization of these tumors.
由于生化无活性和缺乏儿茶酚胺相关症状,头颈部副神经节瘤的准确诊断常常变得复杂,因此准确的解剖学和功能成像技术对于诊断过程至关重要。
评估了 10 例(7 例 SDHD,3 例 SDHB)共 26 例头颈部副神经节瘤患者的解剖学和功能影像学。本研究比较了 5 种不同的功能成像技术[(18)F-氟代二羟苯丙氨酸((18)F-FDOPA)正电子发射断层扫描(PET)、(18)F-氟代多巴胺((18)F-FDA)PET/计算机断层扫描(CT)、(18)F-氟代脱氧葡萄糖((18)F-FDG)PET/CT、(123)I-间碘苄胍((123)I-MIBG)闪烁显像和(111)In-喷曲肽闪烁显像]对头颈部副神经节瘤的定位。
前瞻性(18)F-FDOPA PET 定位了 10 例患者中的 26 例病变,CT/MRI 定位了 21 例病变,(18)F-FDG PET/CT 定位了 20 例病变,(111)In-喷曲肽闪烁显像定位了 25 例病变中的 16 例,(18)F-FDA PET/CT 定位了 26 例病变中的 12 例,(123)I-MIBG 闪烁显像定位了 26 例病变中的 8 例。与遗传表型相关的成像效果差异,即使在目前的小样本量中,也包括 SDHB 突变患者中(18)F-FDA PET/CT 和(123)I-MIBG 闪烁显像的阴性以及 SDHD 突变患者中(18)F-FDG PET/CT 的准确性,而在 SDHB 突变患者中仅 1 例准确性为(18)F-FDG PET/CT。
总的来说,(18)F-FDOPA PET 在定位 SDHx 相关头颈部副神经节瘤方面被证明是最有效的功能成像方式,并且可能是定位这些肿瘤的潜在一线功能成像剂。